About this trial
The study will be a prospective randomized, controlled clinical study. There will be interventional treatment for a total of 30 days. The subjects will complete questionnaires throughout the study at pre-specified timepoints.
Eligibility criteria
Qualifiers
Male or female.
Age 25-59 years.
BMI ≥18.5 and ≤29.9 kg/m².
Currently experiencing issues with sleep quality, falling asleep, staying asleep, or waking during the night.
Disqualifiers
Diagnosed chronic sleep conditions (e.g., insomnia, narcolepsy, REM Behavior Disorder, moderate to severe restless leg syndrome, sleep apnea).
Current use of sleep-tracking technology (e.g., wrist-worn trackers, rings, smartphone apps) that could influence sleep behavior or perception.
Use of hormone therapy (estrogen, progesterone, phytoestrogens) within the last 3 months.
Diagnosed psychiatric disorders including major depressive disorder with acute symptoms, bipolar disorder, generalized anxiety disorder with active symptoms, and PTSD with frequent nightmares.
Trial design
Treatments tested in this trial
- Sleep Supplement